Last reviewed · How we verify
mild-ex-gwarip
Mild-ex-gwarip is a small molecule that targets the SGLT2 receptor.
Mild-ex-gwarip is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | mild-ex-gwarip |
|---|---|
| Also known as | standard code for item: 200005689 |
| Sponsor | Korea Health Industry Development Institute |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, mild-ex-gwarip reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital yeast infections
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- mild-ex-gwarip CI brief — competitive landscape report
- mild-ex-gwarip updates RSS · CI watch RSS
- Korea Health Industry Development Institute portfolio CI